TimesSquare Capital Management LLC Sells 14,635 Shares of Repligen Co. (NASDAQ:RGEN)

TimesSquare Capital Management LLC lessened its stake in shares of Repligen Co. (NASDAQ:RGEN - Free Report) by 5.3% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 260,992 shares of the biotechnology company's stock after selling 14,635 shares during the period. TimesSquare Capital Management LLC owned about 0.47% of Repligen worth $37,567,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. Blue Trust Inc. increased its holdings in Repligen by 113.4% during the third quarter. Blue Trust Inc. now owns 239 shares of the biotechnology company's stock worth $36,000 after buying an additional 127 shares during the last quarter. Resources Management Corp CT ADV purchased a new stake in Repligen during the third quarter worth about $37,000. Quarry LP increased its holdings in Repligen by 796.7% during the third quarter. Quarry LP now owns 269 shares of the biotechnology company's stock worth $40,000 after buying an additional 239 shares during the last quarter. nVerses Capital LLC purchased a new stake in Repligen during the third quarter worth about $45,000. Finally, UMB Bank n.a. increased its holdings in Repligen by 49.1% during the fourth quarter. UMB Bank n.a. now owns 334 shares of the biotechnology company's stock worth $48,000 after buying an additional 110 shares during the last quarter. Hedge funds and other institutional investors own 97.64% of the company's stock.

Analyst Ratings Changes

A number of research firms recently issued reports on RGEN. JPMorgan Chase & Co. raised their price objective on shares of Repligen from $190.00 to $200.00 and gave the stock an "overweight" rating in a report on Friday. StockNews.com upgraded shares of Repligen from a "sell" rating to a "hold" rating in a report on Friday, January 3rd. Canaccord Genuity Group assumed coverage on shares of Repligen in a research note on Tuesday, December 17th. They issued a "hold" rating and a $165.00 target price for the company. Royal Bank of Canada lifted their target price on shares of Repligen from $203.00 to $205.00 and gave the stock an "outperform" rating in a research note on Friday. Finally, Wolfe Research assumed coverage on shares of Repligen in a research note on Thursday, November 14th. They issued a "peer perform" rating for the company. Six investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company. According to data from MarketBeat, Repligen has an average rating of "Moderate Buy" and a consensus price target of $183.36.

Repligen Price Performance

NASDAQ:RGEN traded down $3.68 during mid-day trading on Friday, hitting $158.99. 795,356 shares of the stock traded hands, compared to its average volume of 609,046. The business's 50-day moving average price is $155.22 and its 200 day moving average price is $148.79. The company has a market cap of $8.91 billion, a PE ratio of -429.69, a price-to-earnings-growth ratio of 4.23 and a beta of 0.99. Repligen Co. has a 12-month low of $113.50 and a 12-month high of $203.13. The company has a quick ratio of 8.76, a current ratio of 10.44 and a debt-to-equity ratio of 0.26.

Repligen (NASDAQ:RGEN - Get Free Report) last issued its quarterly earnings data on Thursday, February 20th. The biotechnology company reported $0.44 EPS for the quarter, beating the consensus estimate of $0.41 by $0.03. The company had revenue of $167.55 million during the quarter, compared to analysts' expectations of $167.58 million. Repligen had a negative net margin of 3.36% and a positive return on equity of 3.90%. On average, analysts expect that Repligen Co. will post 1.54 EPS for the current fiscal year.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.